Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Alnylam Pharmaceuticals (ALNY)

Alnylam: Co-founder Phillip Sharp to retire from board effective May 8, 2025

Neutral Impact 2 of 5 leadership Written later

Alnylam co-founder Dr. Phillip A. Sharp informed the board on March 3, 2025 that he will retire as a director effective May 8, 2025. The filing says the retirement did not result from any disagreement with the company, and Dr. Sharp will remain on the Scientific Advisory Board. The change affects board composition but does not alter reported financial results or operations.

Key points

  • Dr. Phillip A. Sharp notified the board on March 3, 2025 of his retirement as a director.
  • Retirement is effective May 8, 2025.
  • Dr. Sharp will continue as a member of the Scientific Advisory Board.
  • The filing states the retirement was not caused by any disagreement with the company.

The filing

CompanyAlnylam Pharmaceuticals (ALNY)
Form8-K, current report
Filed with the SECMar 5, 2025, 4:33 PM ET
Accession number0001178670-25-000031

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.